Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 1 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  2. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  3. US 20260083736

    GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY

    BOEHRINGER INGELHEIM INT [DE] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  4. US 20260060930

    New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases

    BOEHRINGER INGELHEIM INT [DE] · Granted Mar 5, 2026 · Expires Feb 28, 2046

    granted
  5. US 20260055120

    Bicyclic pyrimidinones as inhibitors of NOX4

    BOEHRINGER INGELHEIM INT [DE] · Granted Feb 26, 2026 · Expires Feb 21, 2046

    granted
  6. US 20260008777

    INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE

    BRISTOL MYERS SQUIBB CO [US] · Granted Jan 8, 2026 · Expires Jan 3, 2046

    granted
  7. US 20260001878

    SUBSTITUTED PYRROLOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF TLR9

    BRISTOL MYERS SQUIBB CO [US] · Granted Jan 1, 2026 · Expires Dec 27, 2045

    granted
  8. US 2025333394

    Tiparp Inhibitor Compounds

    ABBVIE INC [US] · Granted Oct 30, 2025 · Expires Oct 25, 2045

    granted
  9. EP 4640274

    LPAR1-INHIBITOREN

    ABBVIE INC [US] · Granted Oct 29, 2025 · Expires Oct 24, 2045

    granted
  10. US 2025304535

    KAT6 Inhibitors

    BEIGENE SWITZERLAND GMBH [CH] · Granted Oct 2, 2025 · Expires Sep 27, 2045

    granted
  11. US 12428415

    Matriptase 2 inhibitors and uses thereof

    Disc Medicine, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  12. US 12428379

    Acylsulfonamide KAT6A inhibitors

    Olema Pharmaceuticals, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  13. US 12428395

    Heterocyclic compounds as kinase inhibitor and uses thereof

    SPEROGENIX THERAPEUTICS LIMITED · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  14. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  15. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  16. US 12419873

    Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases

    ZHUHAI UNITED LABORATORIES CO., LTD. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  17. US 12421231

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  18. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  19. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  20. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Medshine Discovery Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  21. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    CGeneTech (Suzhou, China) CO., Ltd. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  22. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  23. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  24. US 12414981

    JNK inhibitors for use in treating and preventing neurodegenerative disorders

    Northwestern University · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted